Clinical Trial Update: Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating memory-like natural killer cells in combination with nivolumab and relatlimab for advanced or metastatic melanoma after progre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Memory-like natural killer cells
• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Advanced Melanoma, Metastatic Melanoma | Phase 1 | Status: RECRUITING